MiRNA-424-5p Suppresses Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma and Attenuates Expression of O-GlcNAc-Transferase.

O-GlcNAc-transferase (OGT) biomarkers clear cell renal cell cancer (ccRCC) invasion microRNA migration proliferation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Oct 2021
Historique:
received: 16 09 2021
revised: 08 10 2021
accepted: 12 10 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

MicroRNAs (miRNAs) are non-coding post-transcriptional regulators of gene expression that are dysregulated in clear cell renal cell carcinoma (ccRCC) and play an important role in tumor progression. Our prior work identified a subset of miRNAs in pT1 ccRCC tumors, including miR-424-5p, that are associated with an aggressive phenotype. We investigate the impact of this dysregulated miRNA and its protein target O-GlcNAc-transferase (OGT) to better understand the mechanisms behind aggressive stage I ccRCC. The ccRCC cell lines 786-O and Caki-1 were used to assess the impact of miR-424-5p and OGT. Cells were transfected with pre-miR-424-5p, a lentiviral anti-OGT shRNA, or were treated with the demethylating agent 5-Aza-2'-deoxycytidine. Cell proliferation was measured via MT cell viability assay. Cell migration and invasion were analyzed using Transwell assays. The expression of miR-424-5p was determined through qRT-PCR, while OGT protein expression was evaluated through Western blotting. The interaction between miR-424-5p and OGT was confirmed via luciferase reporter assay. The transfection of ccRCC cells with pre-miR-424-5p or anti-OGT shRNA significantly inhibited cell proliferation, migration, and OGT expression, while miR-424-5p also attenuated cell invasion. Addition of the demethylating agent significantly reduced cell proliferation, migration, invasion, and OGT expression, while significantly increasing the expression of miR-424-5p. Altogether, these findings suggest that epigenetic downregulation of miR-424-5p, which in turn augments OGT expression, contributes to the creation of aggressive forms of stage I ccRCC.

Identifiants

pubmed: 34680309
pii: cancers13205160
doi: 10.3390/cancers13205160
pmc: PMC8533684
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : R.K. Mellon Family Foundation
ID : 1
Organisme : Thea Post Foundation
ID : 1
Organisme : Morton E. Goulder Research Endowment Fund
ID : 1

Références

Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Oncol Rep. 2015 May;33(5):2354-60
pubmed: 25708247
Horm Cancer. 2018 Feb;9(1):12-21
pubmed: 28929346
Genes Chromosomes Cancer. 2012 Jul;51(7):707-16
pubmed: 22492545
Cancers (Basel). 2018 Feb 16;10(2):
pubmed: 29462906
Front Oncol. 2020 Oct 27;10:585288
pubmed: 33194731
Pathol Res Pract. 2020 Jan;216(1):152731
pubmed: 31785995
Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):14292-14298
pubmed: 32522876
Nat Genet. 2005 May;37(5):495-500
pubmed: 15806104
Eur Urol. 2018 Dec;74(6):756-763
pubmed: 30143382
RNA. 2004 Oct;10(10):1507-17
pubmed: 15383676
J Gastrointest Cancer. 2021 Mar 6;:
pubmed: 33675468
Braz J Med Biol Res. 2020 Jun 03;53(7):e9029
pubmed: 32520206
J Biol Chem. 2016 Jan 15;291(3):1529-37
pubmed: 26589799
Cancer Biol Ther. 2014 Mar 1;15(3):329-41
pubmed: 24351440
J Neurooncol. 2017 Jun;133(2):247-255
pubmed: 28508328
Biomed Pharmacother. 2018 Jun;102:147-152
pubmed: 29550638
Science. 2013 Apr 19;340(6130):350-3
pubmed: 23493425
J Mol Biol. 2016 Aug 14;428(16):3282-3294
pubmed: 27343361
Cell Physiol Biochem. 2018;45(5):2086-2094
pubmed: 29533945
Urol Oncol. 2020 Oct;38(10):799.e11-799.e22
pubmed: 32534961
J Clin Oncol. 2002 May 1;20(9):2376-81
pubmed: 11981011
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Front Genet. 2020 Nov 23;11:605263
pubmed: 33329753
Cancer Biomark. 2010;9(1-6):461-73
pubmed: 22112490
Onco Targets Ther. 2019 Nov 29;12:10441-10453
pubmed: 31819525
Nat Commun. 2014 Aug 22;5:4718
pubmed: 25146723
Cell Cycle. 2019 Jul;18(14):1601-1618
pubmed: 31135262
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Clin Oncol. 2018 Nov 10;36(32):3251-3258
pubmed: 30183466
Cell Cycle. 2018;17(3):309-318
pubmed: 29228869
Int J Biol Sci. 2019 Jun 4;15(8):1591-1599
pubmed: 31360102
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Cancer Manag Res. 2019 Mar 19;11:2215-2223
pubmed: 30962710
Bioinformatics. 2012 Mar 15;28(6):771-6
pubmed: 22285563
Cancer Biomark. 2021;30(3):343-351
pubmed: 33337348
PLoS One. 2016 Jun 23;11(6):e0157801
pubmed: 27336447
World J Urol. 2011 Jun;29(3):367-73
pubmed: 21229250
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Cancers (Basel). 2019 Oct 28;11(11):
pubmed: 31661791
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Clinics (Sao Paulo). 2013 Jun;68(6):825-33
pubmed: 23778472
Clin Biochem. 2013 Jul;46(10-11):879-900
pubmed: 23518312
J Urol. 2012 Aug;188(2):391-7
pubmed: 22698625
Oncotarget. 2015 Sep 15;6(27):24119-31
pubmed: 26090723
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Thomas J Kalantzakos (TJ)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Travis B Sullivan (TB)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Thales Gloria (T)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

David Canes (D)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Alireza Moinzadeh (A)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Kimberly M Rieger-Christ (KM)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.
Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Classifications MeSH